We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Proteome Sciences plc (PRM) Ordinary 1p

Sell:2.36p Buy:3.20p 0 Change: 0.06p (2.21%)
Market closed Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.36p
Buy:3.20p
Change: 0.06p (2.21%)
Market closed Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.36p
Buy:3.20p
Change: 0.06p (2.21%)
Market closed Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.

Contact details

Address:
Coveham House, Downside Bridge Road
ADDLESTONE
KT11 3EP
United Kingdom
Telephone:
+44 (020) 70432116
Website:
https://www.proteomics.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 13 September 2024 13/09/24
AGM 16 May 2024 16/05/24
Final results 10 April 2024 10/04/24

General stock information

EPIC:
PRM
ISIN:
GB0003104196
Market cap:
£8.03 million
Shares in issue:
295.18 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Mariola Soehngen
    Chief Executive Officer, Executive Director
  • Abdelghani Omari
    Chief Financial Officer, Executive Director
  • Stefan Fuhrmann
    Finance Director
  • Ian Pike
    Chief Scientific Officer, Executive Director
  • Richard Dennis
    Executive Director, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.